Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Janssen Voluntarily Recalls Anticancer Drug Velcade
November 22, 2010
- MTPC to Launch Nearly 10 New Products by FY2015
November 22, 2010
- JT: Pharma Business Driven by Torii
November 22, 2010
- Sales of Ethical Drugs Up 0.2% in September: Crecon Report
November 22, 2010
- Kaken to Increase Its No. of MRs to 800
November 22, 2010
- Yakult Honsha: Elplat Drives Pharma Business
November 22, 2010
- Eribulin Approved by FDA: Eisai
November 22, 2010
- Combined Sales of 23 Listed JPMA Member Companies Up 1.4%
November 22, 2010
- Sato to Launch Switch OTC Steroidal Agent
November 22, 2010
- GRU Criticizes Korosho for Not Discussing Range of OTC-like Drugs to Be Excluded from Insurance Coverage
November 22, 2010
- Kyorin: Sales Up 2.2% Driven by Kipres
November 22, 2010
- Price Settlement Rate 49.8% as of Sept. 30: CEO Kumakura of MEDIPAL
November 22, 2010
- Need for Economic Assessment of Drugs Pointed Out at Chuikyo
November 22, 2010
- Nippon Shinyaku: Cialis Drives Sales
November 22, 2010
- Alfresa: Operating Profits More than Double
November 22, 2010
- Afinitor Approved for Brain Tumors: Novartis
November 22, 2010
- Zeria: Asacol Drives Sales, Profits
November 22, 2010
- Suzuken: Operating Loss Reported for the First Time
November 22, 2010
- Enroll Japanese Patients in Early-Stage Global Studies
November 22, 2010
- Fuso: Generics Make Up for Decreases in Sales
November 22, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…